Re-Kinect

Caroff, Stanley N.; Yeomans, Karen; Lenderking, William R.; Cutler, Andrew J.; Tanner, Caroline M.; Shalhoub, Huda; Pagé, Véronique; Chen, Jun; Franey, Ericha; Yonan, Charles

doi:10.1097/jcp.0000000000001201

Cited by 28 publications

(34 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TD has been associated with decreased quality of life, increased hospitalizations, speech and eating difficulties, cognitive dysfunction, decreased employment, social withdrawal, stigmatization, amplified emotional distress, and increased psychopathology in the underlying psychiatric disorder when patients with TD are compared with non-TD counterparts. 2,11,12,[29][30][31] Although causality has not been established, and TD may be a marker of more severe illness for some patients, these potential negative effects underscore the importance of assessing TD and its impact.…”

Section: Importance Of Assessing the Impact Of Tdmentioning

confidence: 99%

“…More than half of patients with TD reported that their employment status was "disabled" (P = 0.0027 vs patients without TD). 2 Stigma associated with TD can also lead to a perception that individuals with orofacial symptoms are less employable than individuals without TD. 33,34 Negative effects on employment may also be a result of patients with uncontrolled TD avoiding public places and attempting to hide their abnormal movements.…”

Section: Social Functioningmentioning

confidence: 99%

“…Tardive dyskinesia (TD) is a hyperkinetic movement disorder in which patients experience abnormal involuntary movements that occur most often in the orofacial region but can also occur in the neck, trunk, upper and lower extremities, and other muscles (eg, diaphragmatic and pharyngeal musculature). [1][2][3][4][5] TD can occur during or after stopping treatment with dopamine receptor antagonists or partial agonists, including typical (first-generation) and atypical (second-generation) antipsychotics, and some medications used to treat gastrointestinal disorders, such as metoclopramide. 3,[6][7][8] The lifetime prevalence of TD in patients treated with antipsychotics is estimated to be between approximately 15% and 40%, with higher rates reported in older (age >55 years) patients 9 ; higher rates are also observed among women who are postmenopausal.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations

Jackson¹,

Brams²,

Citrome³

et al. 2021

NDT

View full text Add to dashboard Cite

Purpose: Tardive dyskinesia (TD) is a hyperkinetic movement disorder in which patients experience abnormal involuntary movements that can have profound negative impacts on physical, cognitive, and psychosocial functioning. Use of measures to assess the functional impact of TD in routine clinical practice is lacking. To address this gap, an advisory panel of experts in psychiatry and movement disorder neurology was convened to develop consensus recommendations on assessment of the impact of TD on patients' functioning that can be used in clinical practice. Methods: An advisory panel provided recommendations using an iterative process, beginning with a narrative literature review regarding current practices for assessing the impact of TD in clinical settings. A detailed summary was generated, and the advisory panel provided comments about the content and answered questions about assessing TD impact in clinical practice. The panelists' responses were discussed during a virtual meeting held on August 28, 2020. A second meeting on September 25, 2020, focused on developing and refining recommendations for assessment of the impact of TD in clinical practice. At the conclusion of the second meeting, general consensus was reached on all recommendation statements. Results: As part of routine clinical practice, it is imperative to assess the impact of TD on the patient's life to help guide treatment decisions. Key domains for assessing the overall impact of TD include social, physical, vocational, and psychological functioning and the impact of TD on the underlying psychiatric disorder. Assessment of TD impact should be performed at every patient visit. Impact assessments should include consultation with patients, caregivers, and family members. Shared decision-making to initiate TD treatment should consider impact. Conclusion:The impact of TD should be assessed routinely, including the key domains of social, physical, vocational, and psychological functioning and the impact of TD on the underlying psychiatric disorder.

show abstract

Section: Importance Of Assessing the Impact Of Tdmentioning

confidence: 99%

Section: Social Functioningmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations

Jackson¹,

Brams²,

Citrome³

et al. 2021

NDT

View full text Add to dashboard Cite

show abstract

“…The absolute number of people at risk of TD may be growing due to expanding indications and off-label prescribing of antipsychotics [ 8 - 11 ]. While recent studies confirm the impact of TD on quality of life that was often overlooked in the past [ 12 , 13 ], effective treatment of TD using vesicular monoamine transporter-2 inhibitors (VMAT2s) is now available [ 14 , 15 ]. Finally, research into the pharmacology underlying TD may shed light on basal ganglia organization and function.…”

Section: Introductionmentioning

confidence: 99%

Recent Advances in the Pharmacology of Tardive Dyskinesia

Caroff

2020

Clin Psychopharmacol Neurosci

Self Cite

View full text Add to dashboard Cite

Tardive dyskinesia (TD) is a syndrome of abnormal involuntary movements that follows treatment with dopamine D2-receptor antagonists. Recent approval of vesicular monoamine transporter-2 (VMAT2) inhibitors offers hope for reducing the impact of TD. Although these drugs represent a significant advance in patient care and a practical step forward in providing relief for patients with TD, understanding of the pharmacology of TD that could inform future research to prevent and reverse TD remains incomplete. This review surveys evidence for the effectiveness of VMAT2 inhibitors and other agents in the context of theories of pathogenesis of TD. In patients for whom VMAT2 inhibitors are ineffective or intolerable, as well as for extending therapeutic options and insights regarding underlying mechanisms, a review of clinical trial results examined as experimental tests of etiologic hypotheses is worthwhile. There are still compelling reasons for further investigations of the pharmacology of TD, which could generate alternative preventive and potentially curative treatments. Finally, benefits from novel drugs are best realized within an overall treatment strategy addressing the condition and needs of individual patients.

show abstract

“…2020 m. at lik ta me ty ri me pa skelb ta, kad ið 204 pa cien tø, ser gan èiø VD, 75,5 % tei gë esan tys su si drovë jae ar su si gë dae dël sa vo ne va lin gø ju de siø, ku riø ne ga lë jo su val dy ti. To kie jaus mai ga li su stip rin ti jau esa mus psichiat ri nius simp to mus (pvz., pri slëg tà nuo tai kà, ne ri mà) ir pri si dë ti prie stig ma ti za ci jos bei so cia li nës izo lia ci jos [8]. Pas ta rai siais me tais ávy ko ne pa pras tai di de lis po stû mis nuo ni hi lis ti nio po þiû rio á VD, kai li te ra tû ro je pa si ro dë daug pub li ka ci jø, ku rio se ap ta ria mos nau jos áþval gos apie VD pa to fi zio lo gi jà ir nau jus vais tus [9].…”

unclassified

Treatment of tardive dyskinesia caused by long-term antipsychotic use: case reports and literature review

Pabarčiūtė¹,

Karnickas²

2020

View full text Add to dashboard Cite

Įvadas. Vėlyvoji diskinezija – judėjimo sutrikimas, prasidedantis bent keletą mėnesių vartojant dopamino receptorių blokatorius. Šie vaistai apima daugumą vaistų nuo psichozės, kurių vartojimas plačiai taikomas gydant psichikos ligas. Ši neįgalumą sukelianti būklė išliks klinikine šiuolaikinės psichiatrijos dalimi, o pastaraisiais metais literatūroje pasirodęs didelis publikacijų apie vėlyvąją diskineziją skaičius yra didžiulis postūmis šioje srityje. Atvejų aprašymai. 43 metų moteris, serganti paranoidine šizofrenija, 2018 m. hospitalizuota dėl viso kūno nuolatinių nevalingų judesių, itin išreikštų apie 2 metus. Pacientė antipsichotikus vartoja apie 20 metų, pirmieji diskineziniai judesiai pastebėti prieš 10 metų (įvairūs trūkčiojimai) ir aprašyti 2014 m. (čepsėjimas). Pacientei diagnozuota vėlyvoji diskinezija, paskirtas gydymas tetrabenazinu. Pacientės būklė stacionare akivaizdžiai gerėjo, stereotipiški distoniniai-hiperkineziniai galūnių ir liemens judesiai bei kiti simptomai išnyko. Kita pacientė – 55 metų moteris, 2019 m. hospitalizuota dėl nevalingų judesių, reguliariai antipsichotikus vartojusi apie 10 metų dėl kliedesinio sutrikimo. Akatizija ir rankų diskinezijos atsirado prieš 7 metus, pamažu progresavo iki veido, kaklo, rankų, liemens choreoatetoidinių judesių. Hospitalizacijos metu diagnozuota paranoidinė šizofrenija, vėlyvoji diskinezija, paskirtas gydymas tetrabenazinu. Gydant sumažėjo nevalingų judesių amplitudė, pacientė tapo labiau funkcionali. Literatūros apžvalga. Vienas sunkumų psichiatrijoje, gydant vėlyvąją diskineziją, – poreikis tęsti būklę sąlygojusius antipsichotikus. Geriausias pasirinkimas būtų antros kartos atipiniai antipsichotikai. Pirmo pasirinkimo vaistai vėlyvajai diskinezijai gydyti yra VMAT2 inhibitoriai – deutetrabenazinas, valbenazinas, jei šie vaistai neprieinami – tetrabenazinas. Išvados. Norint pateikti patikimas, įrodymais pagrįstas vėlyvosios diskinezijos gydymo rekomendacijas, geriau suprasti jos patofiziologiją, genetinę predispoziciją ir gydymui skirtus preparatus, reikėtų atlikti daugiau, didesnių imčių ir vienodesnių sąlygų tyrimų.

show abstract

Re-Kinect

Abstract: Any pre-existing medical condition, n (%) 0.0886 0.1799 Yes 436 (81.5%) 177 (86.8%) No 99 (18.5%) 27 (13.2%)

Cited by 28 publications

References 32 publications

Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations

Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations

Recent Advances in the Pharmacology of Tardive Dyskinesia

Treatment of tardive dyskinesia caused by long-term antipsychotic use: case reports and literature review

Contact Info

Product

Resources

About